Press releases

All types

News

Press releases - Regulatory

Press releases - Non regulatory

All years

2024

2023

2022

2021

2020

2019

2018

2017

2016

Isofol announces that an investigator-initiated study of arfolitixorin has been published in BJC Reports
Non regulatory press release
GOTHENBURG, Sweden, November 21, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces…
November 21, 2024
Isofol provides an operational update during investor meeting
Non regulatory press release
GOTHENBURG, Sweden, November 20, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), will provide…
November 20, 2024
Isofol appoints nomination committee ahead of the Annual General Meeting 2025
Regulatory press release
GOTHENBURG, Sweden, November 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or…
November 19, 2024
Isofol Medical AB (publ) publishes interim report, January–September 2024
Regulatory press release
GOTHENBURG, Sweden, November 12, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…
November 12, 2024
Isofol announces that an abstract has been accepted for presentation at ASCO GI 2025
Non regulatory press release
GOTHENBURG, SWEDEN, November 11, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces…
November 11, 2024
Isofol invites to investor meeting on November 20, 2024
News
GOTHENBURG, Sweden, October 25, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites…
October 25, 2024
A Late Breaking Abstract concerning arfolitixorin will be presented at ENA 2024 today
Non regulatory press release
GOTHENBURG, SWEDEN, October 23, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces…
October 23, 2024
Isofol announces that a Late Breaking Abstract has been accepted by ENA 2024
Non regulatory press release
GOTHENBURG, SWEDEN, October 9, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces…
October 9, 2024
Isofol strengthens the outlook for further extending the patent protection of its drug candidate arfolitixorin
Regulatory press release
GOTHENBURG, Sweden, September 17, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces…
September 17, 2024
Isofol terminates liquidity guarantee agreement
Regulatory press release
GOTHENBURG, Sweden, September 12, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces…
September 12, 2024
Isofol Medical AB (publ) publishes interim report, January–June 2024
Regulatory press release
GOTHENBURG, Sweden, August 21, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…
August 21, 2024
Isofol appoints Margareta Hagman as new Chief Financial Officer
Regulatory press release
GOTHENBURG, Sweden, July 30, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announced today…
July 30, 2024
Isofol announces new preclinical data supporting the previously communicated clinical development plan for arfolitixorin
Regulatory press release
GOTHENBURG, Sweden, July 16, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces…
July 16, 2024
Isofol announces a post hoc per-protocol analysis of the AGENT study, further supporting arfolitixorin’s continued clinical development
Regulatory press release
GOTHENBURG, Sweden, July 5, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…
July 5, 2024
Isofol’s Chief Financial Officer to leave the company
Regulatory press release
GOTHENBURG, Sweden, June 12, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today…
June 12, 2024
Isofol and Charité sign collaboration agreement on further clinical development of arfolitixorin
Regulatory press release
GOTHENBURG, Sweden, May 24, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…
May 24, 2024
Bulletin from annual general meeting in Isofol Medical AB (publ) held on May 8, 2024
Regulatory press release
Today on May 8, 2024 in Gothenburg – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL),…
May 8, 2024
Isofol Medical AB (publ) publishes interim report, January–March 2024
Regulatory press release
GOTHENBURG, Sweden, May 8, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…
May 8, 2024
Isofol Medical AB (publ) publishes annual report and corporate governance report for 2023
Regulatory press release
GOTHENBURG, Sweden, April 16, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced…
April 16, 2024
Notice to attend the Annual General Meeting held on May 8, 2024 in Isofol Medical AB (publ)
Regulatory press release
GOTHENBURG, Sweden, April 5, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites…
April 5, 2024
Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin
Regulatory press release
GOTHENBURG, Sweden, March 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol”), today…
March 19, 2024
Isofol presents a clinical development plan for arfolitixorin
Regulatory press release
GOTHENBURG, Sweden, March 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol”), today…
March 19, 2024
Isofol invites to investor meeting on March 19
News
GOTHENBURG, Sweden, March 1, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites…
March 1, 2024
Isofol Medical AB (publ) publishes year-end report, January – December 2023
Regulatory press release
GOTHENBURG, Sweden, February 20, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…
February 20, 2024
Isofol’s Board of Directors decides to initiate the planning of clinical studies and will announce a strategic development plan on March 19
Regulatory press release
GOTHENBURG, Sweden, February 14, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), has been…
February 14, 2024
Isofol appoints Magnus Hurst as new Chief Financial Officer
Non regulatory press release
GOTHENBURG, Sweden, January 10, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces…
January 10, 2024
Isofol appoints Petter Segelman Lindqvist as new CEO
Regulatory press release
GOTHENBURG, Sweden, January 9, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today…
January 9, 2024
Bulletin from extraordinary general meeting in Isofol Medical AB (publ) held on January 4, 2024
Non regulatory press release
Today on January 4, 2024 in Gothenburg, Sweden – Isofol Medical AB (publ), (Nasdaq Stockholm:…
January 4, 2024
Isofol presents additional results from laboratory tests with arfolitixorin showing supplementary effects
Regulatory press release
GOTHENBURG, Sweden, December 28, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today…
December 28, 2023
Isofol’s board of directors announces its position on minority shareholder’s proposal ahead of extraordinary general meeting
Non regulatory press release
GOTHENBURG, Sweden, December 13, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today…
December 13, 2023
Isofol has received the first results from laboratory tests of arfolitixorin
Regulatory press release
GOTHENBURG, Sweden, December 7, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today…
December 7, 2023
Isofol is liquidating a subsidiary
Regulatory press release
GOTHENBURG, Sweden, December 1, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…
December 1, 2023
Notice convening the Extraordinary General Meeting in Isofol Medical AB (publ) 4 January 2024
Regulatory press release
GOTHENBURG, Sweden, November 21, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites…
November 21, 2023
Isofol Medical AB (publ) publishes interim report, January–September 2023
Regulatory press release
GOTHENBURG, Sweden, November 10, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…
November 10, 2023
Isofol has obtained a request to call an extraordinary general meeting
Regulatory press release
GOTHENBURG, Sweden, November 9, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), has obtained…
November 9, 2023
Isofol appoints nomination committee ahead of the Annual General Meeting 2024
Regulatory press release
GOTHENBURG, Sweden, November 8, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or…
November 8, 2023
Isofol Medical AB (publ) has taken note of the results from the Modelle 001 study
Non regulatory press release
GOTHENBURG, Sweden, October 5, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), announces…
October 5, 2023
Isofol Medical AB (publ) publishes interim report, January–June 2023
Regulatory press release
GOTHENBURG, Sweden, August 22, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…
August 22, 2023
Isofol presents conclusions from the in-depth analysis of the AGENT study
Non regulatory press release
Gothenburg, Sweden, July 4, 2023 – Isofol Medical AB (publ) today presents the conclusions from…
July 4, 2023
Isofol’s Board of Directors appoints Roger Tell as acting CEO of the company
Regulatory press release
Gothenburg, Sweden, June 22, 2023 – Isofol Medical AB (publ) announces today that its Board…
June 22, 2023
CEO resigns at his own request in Isofol Medical AB (publ)
Regulatory press release
Gothenburg, Sweden, June 21, 2023 – Isofol Medical AB (publ) announces today that Thomas Andersson,…
June 21, 2023
Changes in the board at Isofol Medical AB (publ)
Regulatory press release
Gothenburg, Sweden, June 7, 2023 – Isofol Medical AB (publ) announces today that its Board…
June 7, 2023
Bulletin from annual general meeting in Isofol Medical AB (publ) held on May 3, 2023
Regulatory press release
Today on May 3, 2023 in Gothenburg – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL),…
May 3, 2023
Isofol Medical AB (publ) publishes interim report, January–March 2023
Regulatory press release
GOTHENBURG, Sweden, May 3, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…
May 3, 2023
Isofol initiates preclinical evaluation of arfolitixorin with Oncosyne AS
Non regulatory press release
Gothenburg, Sweden, April 28, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today…
April 28, 2023
Invitation to presentation of Isofol´s report for the first quarter of 2023
Non regulatory press release
GOTHENBURG, Sweden, April 25, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will…
April 25, 2023
Isofol Medical AB (publ) publishes annual report and corporate governance report for 2022
Regulatory press release
GOTHENBURG, Sweden, April 6, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced…
April 6, 2023
Isofols appoints Roy Jonebrant as new acting Chief Financial Officer
Regulatory press release
Gothenburg, Sweden, March 17, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today…
March 17, 2023
Isofol initiates a stepwise process for the continued development of its drug candidate arfolitixorin
Non regulatory press release
Gothenburg, Sweden, March 6, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today…
March 6, 2023
Isofol’s board appoints Thomas Andersson as new CEO of the company
Regulatory press release
Gothenburg, Sweden, February 28, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today…
February 28, 2023
Bulletin from Extraordinary General Meeting in Isofol Medical AB (publ) held on February 28, 2023
Regulatory press release
Today on February 28, 2023 in Gothenburg – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL),…
February 28, 2023
Isofol Medical AB (publ) publishes year-end report, January – December 2022
Regulatory press release
GOTHENBURG, Sweden, February 22, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…
February 22, 2023
Bulletin from Extraordinary General Meeting in Isofol Medical AB (publ) held on February 13, 2023
Regulatory press release
Today on February 13, 2023 in Gothenburg – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL),…
February 13, 2023
Invitation to presentation of Isofol´s report for the fourth quarter of 2022
Non regulatory press release
GOTHENBURG, Sweden, February 9, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will…
February 9, 2023
Isofol has obtained a request to call for an extraordinary general meeting
Regulatory press release
GOTHENBURG, Sweden, January 30, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), has obtained…
January 30, 2023
Isofol invites to an informational meeting on January 30 prior to extraordinary general meeting
Regulatory press release
GOTHENBURG, Sweden, January 20, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), yesterday…
January 20, 2023
Notice convening the extraordinary general meeting in Isofol Medical AB (publ) 13 February 2023
Regulatory press release
GOTHENBURG, Sweden, January 19, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites…
January 19, 2023
Isofol Medical’s Board of Directors intends to call an extraordinary general meeting with proposals for dividends and liquidation of the company
Regulatory press release
GOTHENBURG, Sweden, January 19, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), decided today…
January 19, 2023
Isofol Medical CFO and Deputy CEO Gustaf Albèrt to step down during 2023
Regulatory press release
GOTHENBURG, Sweden, December 21, 2022 – Isofol Medical AB (publ) announced today that Chief Financial…
December 21, 2022
CEO Ulf Jungnelius to leave Isofol Medical on June 1, 2023
Regulatory press release
GOTHENBURG, Sweden, November 28, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today…
November 28, 2022
Final data from the AGENT study confirms topline results
Regulatory press release
GOTHENBURG, Sweden, November 25, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today…
November 25, 2022
Isofol Medical AB (publ) publishes interim report, January–September 2022
Regulatory press release
GOTHENBURG, Sweden, November 11, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…
November 11, 2022
Isofol appoints nomination committee ahead of the Annual General Meeting 2023
Regulatory press release
GOTHENBURG, Sweden, November 3, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or…
November 3, 2022
Invitation to presentation of Isofol’s report for the third quarter of 2022
Non regulatory press release
GOTHENBURG, Sweden, October 27, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will…
October 27, 2022
Isofol reports data from the AGENT study
Regulatory press release
GOTHENBURG, Sweden, 7 september 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) today reported…
September 7, 2022
Isofol provides update on the AGENT study
Regulatory press release
GOTHENBURG, Sweden, August 31, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announced…
August 31, 2022
Isofol Medical AB (publ) publishes interim report, January–June 2022
Regulatory press release
GOTHENBURG, Sweden, August 23, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…
August 23, 2022
Invitation to presentation of Isofol´s report for the second quarter of 2022
Non regulatory press release
GOTHENBURG, Sweden, August 15, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will…
August 15, 2022
Isofol Announces Topline Results of Phase III AGENT Study – Did Not Meet Primary or Key Secondary Endpoints
Regulatory press release
GOTHENBURG, Sweden, August 3, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced…
August 3, 2022
Isofol receives approval of biomarker analysis patent and intention-to-grant patent application for study dose regimen in Europe
Non regulatory press release
GOTHENBURG, Sweden, July 26, 2022 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq Stockholm: ISOFOL), today announced…
July 26, 2022
Isofol updates start time of live-streamed R&D event on June 20 to 14:00 CEST
Non regulatory press release
GOTHENBURG, Sweden, June 17, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today…
June 17, 2022
Isofol invites to a live-streamed R&D Event on June 20 at 12.30 CEST
Non regulatory press release
GOTHENBURG, Sweden, June 14, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today…
June 14, 2022
Bulletin from Annual General Meeting in Isofol Medical AB (publ) held on May 19, 2022
Regulatory press release
Today on May 19, 2022 in Gothenburg – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL),…
May 19, 2022
Isofol Medical AB (publ) publishes interim report, January–March 2022
Regulatory press release
GOTHENBURG, Sweden, May 12, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…
May 12, 2022
Invitation to presentation of Isofol’s report for the first quarter of 2022
Non regulatory press release
GOTHENBURG, Sweden, May 3, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will…
May 3, 2022
Isofol Medical AB (publ) publishes annual report and corporate governance report for 2021
Regulatory press release
GOTHENBURG, Sweden, April 27, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced…
April 27, 2022
Isofol announces start of study data analysis of phase III AGENT study in advanced metastatic colorectal cancer
Non regulatory press release
GOTHENBURG, Sweden, April 22, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced…
April 22, 2022
Notice to attend the Annual General Meeting held on May 19, 2022 in Isofol Medical AB (publ)
Regulatory press release
GOTHENBURG, Sweden, April 12, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites…
April 12, 2022
Isofol Medical AB’s (publ) Nomination Committee proposes New Chair of the Board
Regulatory press release
GOTHENBURG, Sweden, April 8, 2022 – The Nomination Committee of Isofol Medical AB (publ) (Nasdaq…
April 8, 2022
Isofol Medical AB (publ) publishes year-end report, January – December 2021
Regulatory press release
GOTHENBURG, Sweden, February 24, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…
February 24, 2022
Invitation to presentation of Isofol’s year-end report 2021 on February 24, 2022
Non regulatory press release
GOTHENBURG, Sweden, February 14, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will…
February 14, 2022
Isofol recognizes World Cancer Day on February 4
News
Today, February 4, is World Cancer Day (https://www.worldcancerday.org/), and we at Isofol are sending our thoughts…
February 4, 2022
Isofol Medical AB (publ) appoints Jenny Sundqvist as Chief Commercial Officer
Non regulatory press release
GOTHENBURG, Sweden, December 10, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced…
December 10, 2021
Isofol Medical AB (publ) invites to an audiocast on December 6 at 08.00 a.m. CET
Non regulatory press release
GOTHENBURG, Sweden, December 5, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced on…
December 5, 2021
Isofol Medical AB (publ) will not reach 300 PFS events in the AGENT study with current censoring rules based on FDA decision
Regulatory press release
GOTHENBURG, Sweden, December 3, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today…
December 3, 2021
Isofol Medical AB (publ) receives FDA Fast Track Designation for arfolitixorin in advanced colorectal cancer (mCRC)
Regulatory press release
GOTHENBURG, Sweden, November 23, 2021 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq Stockholm: ISOFOL), announced today…
November 23, 2021
Isofol appoints nomination committee ahead of the Annual General Meeting 2022
Regulatory press release
GOTHENBURG, Sweden, November 19, 2021 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or…
November 19, 2021
Isofol Medical AB (publ) publishes interim report for January – September 2021
Regulatory press release
GOTHENBURG, Sweden, November 11, 2021 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today…
November 11, 2021
Trading in Isofol’s shares commences today on Nasdaq Stockholm
Non regulatory press release
GOTHENBURG, Sweden, October 21, 2021 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or…
October 21, 2021
Isofol Medical AB (publ) publishes prospectus and new financial information in connection with listing on Nasdaq Stockholm
Regulatory press release
GOTHENBURG, Sweden, October 18, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…
October 18, 2021
Isofol Medical AB (publ) intends to list its shares on Nasdaq Stockholm
Non regulatory press release
GOTHENBURG, Sweden, October 15, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…
October 15, 2021
Company presentation at LSX Nordic Congress 2021
News
From September 7-17 Isofol participated in LSX Nordic Congress, an opportunity for 1:1 meetings with…
September 22, 2021
Bulletin from Annual General Meeting in Isofol Medical AB (publ) held on June 23, 2021
Regulatory press release
Today on June 23, 2021 in Gothenburg – Isofol Medical AB (publ), (Nasdaq First North…
June 23, 2021
Isofol raises SEK 500 million in oversubscribed rights issue and exercised over-allotment option
Regulatory press release
GOTHENBURG, Sweden, June 14, 2021 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth…
June 14, 2021
Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 400 million
Regulatory press release
GOTHENBURG, Sweden, May 25, 2021 – Isofol Medical AB’s (publ), (Nasdaq First North Premier Growth…
May 25, 2021
Isofol’s Board of Directors resolves on a fully guaranteed preferential rights issue of approximately SEK 400 million
Regulatory press release
GOTHENBURG, Sweden, May 18, 2021 – Isofol Medical AB’s (publ), (Nasdaq First North Premier Growth…
May 18, 2021
Isofol completes recruitment of Japanese patients in the global phase III AGENT study
Non regulatory press release
GOTHENBURG, Sweden, May 6, 2021 – In December 2020, Isofol Medical AB (publ) (“Isofol”), (Nasdaq…
May 6, 2021
Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 400 million and a potential over-allotment option of up to approximately SEK 100 million
Regulatory press release
GOTHENBURG, Sweden, April 28, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…
April 28, 2021
Isofol receives notice that Clinical Use Patent in Europe for Drug Candidate arfolitixorin will be approved
Non regulatory press release
GOTHENBURG, Sweden, March 22, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…
March 22, 2021
Invitation to a conference call and webcast in connection with Isofol receiving recommendation to complete the global Phase III AGENT study for market registration as planned with 440 patients
Non regulatory press release
GOTHENBURG, Sweden, March 22, 2021 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier…
March 22, 2021
Isofol receives recommendation from iDSMB to complete the global Phase III AGENT study for market registration as planned with 440 patients
Regulatory press release
GOTHENBURG, Sweden, March 19, 2021 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier…
March 19, 2021
Isofol to present gene expression results from the completed Phase I/IIa ISO-CC-005 study today at ASCO-GI 2021 and updates of the timing of the interim analysis in the AGENT study
Non regulatory press release
GOTHENBURG, Sweden, January 15, 2021 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier…
January 15, 2021
Isofol reaches 440 patients in global Phase III AGENT study
Non regulatory press release
GOTHENBURG, Sweden, December 9, 2020 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier…
December 9, 2020
Invitation to a conference call and webcast by Isofol in connection with the entered license agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada
Non regulatory press release
GOTHENBURG, Sweden, November 2, 2020 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier…
November 2, 2020
Isofol announces licensing agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada
Regulatory press release
GOTHENBURG, Sweden, November 2, 2020 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier…
November 2, 2020
55 % Overall Response Rate on the safety extension cohorts of the ISO-CC-005 Phase I/IIa study
Non regulatory press release
GOTHENBURG, Sweden, September 30, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…
September 30, 2020
Strengthened patent protection for arfolitixorin in Japan
Non regulatory press release
GOTHENBURG, Sweden, September 1, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…
September 1, 2020
Invitation to a conference call and webcast by Isofol in connection with the entered license agreement with Solasia
Non regulatory press release
GOTHENBURG, Sweden, August 13, 2020 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier…
August 13, 2020
Isofol enters licensing agreement with Solasia to develop and commercialize arfolitixorin in Japan
Regulatory press release
GOTHENBURG, Sweden, August 13, 2020 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier…
August 13, 2020
Isofol’s CEO Ulf Jungnelius has subscribed for all warrants
Non regulatory press release
GOTHENBURG, Sweden, August 4, 2020 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq First North Premier Growth…
August 4, 2020
A milestone is reached with the inclusion of 330 patients in the AGENT-study – opening up for the interim analysis
Non regulatory press release
GOTHENBURG, Sweden, July 21, 2020 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq First North Premier Growth…
July 21, 2020
AGENT study update with regards to COVID-19
Non regulatory press release
GOTHENBURG, Sweden, July 10, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth…
July 10, 2020
Isofol’s rights issue oversubscribed
Regulatory press release
GOTHENBURG, Sweden, June 3, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth…
June 3, 2020
Consortium of investors acquires subscription rights from Isofol´s founder Professor Bengt Gustavsson
Non regulatory press release
GOTHENBURG, Sweden, May 29, 2020 – Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth…
May 29, 2020
Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 150 million
Regulatory press release
GOTHENBURG, Sweden, May 14, 2020 – Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth…
May 14, 2020
Isofol’s Board of Directors resolve on a fully guaranteed preferential rights issue of approximately SEK 150 million
Regulatory press release
GOTHENBURG, Sweden, May 7, 2020 – Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth…
May 7, 2020
Isofol’s drug candidate arfolitixorin receives additional clinical patent approval in the United States
Regulatory press release
GOTHENBURG, Sweden, May 5, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…
May 5, 2020
Information in relation to COVID-19
Non regulatory press release
GOTHENBURG, Sweden, April 2, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…
April 2, 2020
Gene expression data from new analysis method supports that a larger proportion of patients will benefit from arfolitixorin
Non regulatory press release
GOTHENBURG, Sweden, March 30, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…
March 30, 2020
Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 150 million and a potential over-allotment option of up to approximately SEK 30 million
Regulatory press release
GOTHENBURG, Sweden, March 30, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth…
March 30, 2020
The first patient included in Japan in Isofol’s Phase 3 AGENT study
Non regulatory press release
GOTHENBURG, Sweden, February 18 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)…
February 18, 2020
Gene expression analysis method has been validated by a commercial laboratory
Non regulatory press release
GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL),…
January 30, 2020
Over 200 patients now randomized in the Global Phase 3 AGENT Study
Non regulatory press release
GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL),…
January 30, 2020
The Phase 1/2a study ISO-CC-005 is completed
Non regulatory press release
GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL),…
January 30, 2020
The first patient included in Australia in Isofol’s Phase 3 AGENT study
Non regulatory press release
GOTHENBURG, Sweden, January 24 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)…
January 24, 2020
Patent approved in Japan for Isofol’s drug candidate arfolitixorin
Non regulatory press release
GOTHENBURG, Sweden, December 20, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL).…
December 20, 2019
Patent detecting how patients respond to folate-based cancer treatment approved in the USA
Regulatory press release
GOTHENBURG, Sweden, December 13, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…
December 13, 2019
Isofol to Expand Global Phase 3 AGENT Trial in First-Line Metastatic Colorectal Cancer to Australia
Non regulatory press release
GOTHENBURG, Sweden, November 18, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…
November 18, 2019
Isofol’s board appoints Dr. Jarl Ulf Jungnelius as new CEO of the company
Regulatory press release
GOTHENBURG, Sweden, November 13, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…
November 13, 2019
Isofol Receives Positive Feedback from PMDA in Japan, Expanding Ongoing Global Pivotal Phase 3 AGENT Trial in First Line Metastatic Colorectal Cancer
Non regulatory press release
GOTHENBURG, Sweden, October 18, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…
October 18, 2019
Isofol Announces Presentation on the Global Phase 3 Study of arfolitixorin in Metastatic Colorectal Cancer at 2019 ESMO Congress
Non regulatory press release
GOTHENBURG, Sweden, September 29, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…
September 29, 2019
Isofol Announces that an Abstract has been Accepted for Presentation at the 2019 ESMO Congress
Non regulatory press release
GOTHENBURG, Sweden, September 12, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…
September 12, 2019
Isofol Announces Management Team Evolution with Appointment of Dr. Roger Tell as Chief Medical Officer
Non regulatory press release
GOTHENBURG, Sweden, August 15, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…
August 15, 2019
Isofol Announces Recent Advisory Board Meeting Covering Development Plan for arfolitixorin
News
GOTHENBURG, Sweden, July 15, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…
July 15, 2019
Isofol Receives Clinical Use Patent Approval in the United States for Drug Candidate arfolitixorin
Regulatory press release
GOTHENBURG, Sweden, June 25, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…
June 25, 2019
Isofol Announces Election of Three New Board Members
News
GOTHENBURG, Sweden, June 10, 2019 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL),…
June 10, 2019
Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States
Regulatory press release
GOTHENBURG, Sweden, May 21, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…
May 21, 2019
Isofol Reports 58 % Overall Response Rate in Patients with Metastatic Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin
Regulatory press release
GOTHENBURG, Sweden, May 8, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…
May 8, 2019
Isofol Medical AB (publ) appoints Carnegie Investment Bank AB (publ) to Financial advisor
News
GOTHENBURG, Sweden, February 27, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…
February 27, 2019
Isofol Reports All Employees Participate in Newly Created Share Warrant Program
News
GOTHENBURG, Sweden, February 1, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…
February 1, 2019
Isofol has participated in the Empowered Patient Podcast
News
In honor of World Cancer Day on February 4, we would like to share a…
January 31, 2019
Isofol Reports Early Tumor Shrinkage in Patients with Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin
Regulatory press release
GOTHENBURG, Sweden, January 17, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…
January 17, 2019
First patient enrolled in Isofol’s Pivotal Phase 3 AGENT study in 1st line metastatic colorectal cancer
Regulatory press release
GOTHENBURG, Sweden, December 18, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)…
December 18, 2018
Isofol Strengthens Executive Management Team with the Appointment of Roger Tell, MD, PhD, as Chief Scientific Officer and Senior Vice President of Clinical Development
News
GOTHENBURG, Sweden, November 19, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…
November 19, 2018
Isofol Announces the Appointment of Robert Marchesani as an Advisor to its Board of Directors
News
GOTHENBURG, Sweden, November 16, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…
November 16, 2018
Isofol Announces Initiation of a Pivotal Phase 3 Clinical Trial of arfolitixorin for the Treatment of Metastatic Colorectal Cancer
Regulatory press release
GOTHENBURG, Sweden, November 15, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)…
November 15, 2018
New Chairman and extended board at Isofol Medical AB (publ)
Non regulatory press release
Isofol Medical AB (publ), developing arfolitixorin as treatment for advanced colorectal cancer is calling an…
September 11, 2018
Patent approved in the United States for Isofol’s drug candidate arfolitixorin
Regulatory press release
The patent now approved in the United States expires in 2037 and covers both the…
August 31, 2018
Redeye and Isofol are inviting to the live broadcast of pre-ASCO on May 28th
News
In connection to this year’s major cancer congress ASCO (American Society of Clinical Oncology (https://www.asco.org/)) in…
May 24, 2018
Isofol announces that an abstract with new research resultshas been published for this year’s ASCO congress in Chicago
Regulatory press release
Isofol Medical AB (publ) announces that a scientific abstract has been published for this year’s…
May 15, 2018
Isofol reports FDAs feedback from the ongoing special protocol assessment (SPA) process
Regulatory press release
In March 2018, Isofol Medical AB (publ) submitted a Special Protocol Assessment (SPA) to the…
May 3, 2018
Isofol announces that an abstract describing a genetic prediction of treatment response in CRC treatment to be unveiled at ASCO 2018
Non regulatory press release
Isofol Medical AB (publ) announces that an abstract describing correlation between expression levels of folate-related…
April 10, 2018
Isofol Medical has selected arfolitixorin-dose for the phase III pivotal study ISO-CC-007
Non regulatory press release
The selected dose for the drug candidate arfolitixorin of 120 mg/m2, (approximately 200 mg for…
March 19, 2018
Isofol Medical adopts the World Health Organization recommended name (INN) arfolitixorin for Modufolin®
Non regulatory press release
Isofol Medical AB (publ) today announce that the company will in the future be adopting…
February 19, 2018
Isofol reports successful outcome from the scientific advice with the EMA
Regulatory press release
Isofol Medical AB (publ) has received positive feedback in scientific advice from the European Medicines…
February 8, 2018
Isofol’s CEO, directors and employees converts stock – and employee options and subscribe shares for SEK 7 655 136
Non regulatory press release
The incentive program consisting of stock – and employee options in Isofol Medical AB, which…
January 24, 2018
Positive treatment results with Modufolin® (arfolitixorin) will be published at a cancer congress (ASCO) in the US
Non regulatory press release
Prior to this year’s Gastrointestinal (GI) Cancers Symposium of the American Society of Clinical Oncology…
January 18, 2018
Successful End-of-Phase 2 meeting with FDA and Phase 3 Program for Modufolin® agreed
Regulatory press release
Isofol Medical AB (publ), developing Modufolin®(arfolitixorin) as treatment for advanced colorectal cancer, has had a…
January 17, 2018
Isofol reports positive efficacy data for Modufolin® (arfolitixorin) from patients treated for metastatic colorectal cancer
Non regulatory press release
Isofol Medical AB (publ), a clinical oncology company, reports efficacy data for Modufolin® (arfolitixorin) from…
January 11, 2018
Isofol to present at the 10th Annual Biotech Showcase Conference
Non regulatory press release
Isofol Medical AB (publ), a clinical oncology company, announces that Chief Executive Officer Anders Rabbe…
January 4, 2018
Isofol announces that an abstract regarding Modufolins® efficacy in colorectal cancer treatment will be presented at ASCO-GI 2018
News
Isofol Medical AB (publ) announces that an abstract regarding Modufolins® efficacy in colorectal cancer treatment…
November 27, 2017
Isofol appoints Gustaf Albèrt as Chief Financial Officer
Non regulatory press release
Isofol Medical AB (publ) has recruited Gustaf Albèrt as Chief Financial Officer. With extensive experience…
October 3, 2017
Isofol announces that Modufolin® as a rescue therapy in the treatment of osteosarcoma in children is safe and preventive of HDMTX toxicities
Regulatory press release
Isofol Medical AB (publ) announces that results from the clinical ISO-MTX-003 study suggest that Modufolin®…
September 11, 2017
Isofol Medical announces successful Type C meeting with FDA regarding its drug candidate, Modufolin® for treatment of metastatic colorectal cancer
Non regulatory press release
Isofol Medical AB (publ) announces the completion of a successful Type-C meeting with the FDA…
September 4, 2017
From the ongoing ISO-CC-005 study, Isofol reports initial indications of efficacy of Modufolin® in patients with metastatic colorectal cancer
Non regulatory press release
Isofol Medical AB (publ), a clinical oncology company, announces that the initial indications of Modufolin®…
August 24, 2017
Isofols appoints Sven Erickson as Chief Commercial Officer
Non regulatory press release
In preparation for partnering negotiations with pharma companies Isofol Medical AB (publ) announces the appointment…
August 18, 2017
Isofol establish cooperation with Prof. Sten Nilsson and Dr. Alain Herrera in preparation for the upcoming pivotal trial with Modufolin®
Non regulatory press release
Isofol Medical AB (publ) announces that Professor Sten Nilsson, an experienced industry advisor and principal…
August 16, 2017
Isofol announces that an abstract about Modufolin® in osteosarcoma treatment will be presented at ESMO 2017
Non regulatory press release
Isofol Medical AB (publ) announces that an abstract about Modufolin® has been accepted to be…
July 24, 2017
Scrip Intelligence, a leading source of news and strategic analysis for the global pharmaceutical industry, publish article about Isofol Medical
Non regulatory press release
John Davis, journalist and editor for more than 30 years, of Scrip Intelligence recently interviewed…
July 20, 2017
Isofol has enrolled and dosed its first group of patients in the IND-study ISO-FF-001
Non regulatory press release
Isofol Medical AB (publ) announced today that the first six patients were enrolled and dosed…
July 5, 2017
New scientific findings strengthen rationale and motivation for Isofol Medical to conduct the pivotal ISO-CC-007 study
Regulatory press release
Isofol Medical AB (publ) announced today that academic researchers collaborating with Isofol have presented results…
July 3, 2017
Isofol has initiated five additional study sites in the ISO-CC-005 study in which Modufolin® is evaluated in colorectal cancer
Non regulatory press release
Isofol Medical AB (publ) announced today that the last one of five additional study sites…
June 21, 2017
Isofol Announces Publication of an Abstract for the 2017 ASCO Annual Meeting
Non regulatory press release
Isofol Medical AB (publ) announces publication of an abstract regarding failure rate of standard rescue…
May 22, 2017
Pareto Securities has notified Isofol Medical AB that stabilisation measures regarding the Company’s shares have been taken
Regulatory press release
In connection with the offering to acquire newly issued shares in Isofol and the listing…
May 5, 2017
Isofol accepted for presentation of abstract at the 2017 ASCO annual meeting
Non regulatory press release
Isofol Medical AB (publ) announces that an abstract has been accepted to be presented at…
May 3, 2017
Pareto Securities has notified Isofol Medical AB (publ) that stabilisation measures regarding the Company’s shares have been taken
Regulatory press release
In connection with the offering to acquire newly issued shares in Isofol and the listing…
April 25, 2017
Pareto Securities has notified Isofol Medical AB that stabilisation measures regarding the Company’s shares have been taken
Non regulatory press release
For a complete press release follow the link http://isofol.se/en/ipo/ For additional information, please contact: Anders Rabbe, Managing…
April 12, 2017
Isofol has successfully completed the ISO-MTX-003 study in which Modufolin® is evaluated as rescue therapy
Non regulatory press release
Isofol Medical AB announced today that the study ISO-MTX-003 evaluating Modufolin® as rescue therapy (after…
April 11, 2017
Isofol’s largest shareholder and co-founder acquires shares in the company
Non regulatory press release
Isofol Medical AB (publ) announces today that its largest shareholder and co-founder, Bengt Gustavsson, now…
April 4, 2017
Isofol’s Chairman of the Board acquires shares in the company
Non regulatory press release
Isofol Medical AB (publ) announces that its Chairman of the Board, Jan-Eric Österlund, now acquired…
April 4, 2017
Isofol Medical announces the outcome of the Offering – trading on Nasdaq First North Premier commences today
Regulatory press release
Isofol Medical AB (publ), a clinical stage pharmaceutical company, hereby announces that the offering of…
April 4, 2017
Invitation: Isofol will present it’s contemplated IPO in Stockholm on March 29
Non regulatory press release
In connection with the contemplated IPO of Isofol Medical on Nasdaq First North Premier, we…
March 21, 2017
Invitation: Isofol will present it’s contemplated IPO in Göteborg on March 22
Non regulatory press release
In connection with the contemplated IPO of Isofol Medical on Nasdaq First North Premier, we…
March 21, 2017
Listing of Isofol Medical on Nasdaq First North Premier and publication of prospectus
Non regulatory press release
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN…
March 20, 2017
Isofol announces its intention to list on Nasdaq First North Premier
Non regulatory press release
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN…
March 13, 2017
ISOFOL FILES IMPORTANT NEW US PATENT APPLICATION
Non regulatory press release
Isofol Medical AB (publ) today announces that a new patent application was filed, on February…
February 20, 2017
FDA CLEARS ISOFOL’S IND APPLICATION TO START CLINICAL PROGRAM WITHIN COLORECTAL CANCER WITH MODUFOLIN®
Non regulatory press release
Isofol Medical AB announces that the US Food and Drug Administration (FDA) has cleared Isofol’s…
January 24, 2017
ISOFOL MEDICAL PRESENT AT AKTIETORGET INVESTOR MEETING
Non regulatory press release
Isofol Medical AB presented at the AktieTorget investor meeting on Wednesday, October 5. This was…
October 7, 2016
ISOFOL MEDICAL HAS SUCCESSFULLY ADVANCED TO THE NEXT DOSE LEVEL OF MODUFOLIN® IN A PHASE I/II CLINICAL TRIAL IN COLORECTAL CANCER.
Non regulatory press release
Isofol Medical AB today announced initiation of the next dose level of Modufolin®, in combination…
June 2, 2016
ISOFOL MEDICAL SHARE ISSUE OVERSUBSCRIBED, SECURING OVER SEK 39 MILLION TO STRENGTHEN THE ONGOING PHASE II CLINICAL DEVELOPMENT PROGRAM OF MODUFOLIN®
Non regulatory press release
Isofol Medical AB, a clinical stage pharmaceutical company, developing novel products for unmet needs within…
March 14, 2016

Cookie	Duration	Description
__cfruid	session	Cloudflare sets this cookie to identify trusted web traffic.
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Analytics" category .
cookielawinfo-checkbox-functional	1 year	The cookie is set by the GDPR Cookie Consent plugin to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Necessary" category .
cookielawinfo-checkbox-others	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to store the user consent for cookies in the category "Others".
cookielawinfo-checkbox-performance	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to store the user consent for cookies in the category "Performance".
PHPSESSID	session	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy	1 year	The cookie is set by the GDPR Cookie Consent plugin to store whether or not the user has consented to the use of cookies. It does not store any personal data.

Cookie	Duration	Description
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_gid	1 day	Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
CONSENT	2 years	YouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.

Cookie	Duration	Description
VISITOR_INFO1_LIVE	5 months 27 days	A cookie set by YouTube to measure bandwidth that determines whether the user gets the new or old player interface.
YSC	session	YSC cookie is set by Youtube and is used to track the views of embedded videos on Youtube pages.
yt-remote-connected-devices	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.
yt-remote-device-id	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.

Cookie	Duration	Description
_fanplay_session	1 year	No description
BIGipServer~magenta~mag-c-http-http-xhttpd-http-xhttpd-http-80	session	No description
device-info	session	No description available.
svd-ab	past	No description
svd-ab-seg	1 month	No description available.
svd-b2b	1 month	No description
svd-paywall-ab-seg	7 days	No description

Isofol announces that an investigator-initiated study of arfolitixorin has been published in BJC Reports

Isofol provides an operational update during investor meeting

Isofol appoints nomination committee ahead of the Annual General Meeting 2025

Isofol Medical AB (publ) publishes interim report, January–September 2024

Isofol announces that an abstract has been accepted for presentation at ASCO GI 2025

Isofol invites to investor meeting on November 20, 2024

A Late Breaking Abstract concerning arfolitixorin will be presented at ENA 2024 today

Isofol announces that a Late Breaking Abstract has been accepted by ENA 2024

Isofol strengthens the outlook for further extending the patent protection of its drug candidate arfolitixorin

Isofol terminates liquidity guarantee agreement

Isofol Medical AB (publ) publishes interim report, January–June 2024

Isofol appoints Margareta Hagman as new Chief Financial Officer

Isofol announces new preclinical data supporting the previously communicated clinical development plan for arfolitixorin

Isofol announces a post hoc per-protocol analysis of the AGENT study, further supporting arfolitixorin’s continued clinical development

Isofol’s Chief Financial Officer to leave the company

Isofol and Charité sign collaboration agreement on further clinical development of arfolitixorin

Bulletin from annual general meeting in Isofol Medical AB (publ) held on May 8, 2024

Isofol Medical AB (publ) publishes interim report, January–March 2024

Isofol Medical AB (publ) publishes annual report and corporate governance report for 2023

Notice to attend the Annual General Meeting held on May 8, 2024 in Isofol Medical AB (publ)

Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin

Isofol presents a clinical development plan for arfolitixorin

Isofol invites to investor meeting on March 19

Isofol Medical AB (publ) publishes year-end report, January – December 2023

Isofol’s Board of Directors decides to initiate the planning of clinical studies and will announce a strategic development plan on March 19

Isofol appoints Magnus Hurst as new Chief Financial Officer

Isofol appoints Petter Segelman Lindqvist as new CEO

Bulletin from extraordinary general meeting in Isofol Medical AB (publ) held on January 4, 2024

Isofol presents additional results from laboratory tests with arfolitixorin showing supplementary effects

Isofol’s board of directors announces its position on minority shareholder’s proposal ahead of extraordinary general meeting

Isofol has received the first results from laboratory tests of arfolitixorin

Isofol is liquidating a subsidiary

Notice convening the Extraordinary General Meeting in Isofol Medical AB (publ) 4 January 2024

Isofol Medical AB (publ) publishes interim report, January–September 2023

Isofol has obtained a request to call an extraordinary general meeting

Isofol appoints nomination committee ahead of the Annual General Meeting 2024

Isofol Medical AB (publ) has taken note of the results from the Modelle 001 study

Isofol Medical AB (publ) publishes interim report, January–June 2023

Isofol presents conclusions from the in-depth analysis of the AGENT study

Isofol’s Board of Directors appoints Roger Tell as acting CEO of the company

CEO resigns at his own request in Isofol Medical AB (publ)

Changes in the board at Isofol Medical AB (publ)

Bulletin from annual general meeting in Isofol Medical AB (publ) held on May 3, 2023

Isofol Medical AB (publ) publishes interim report, January–March 2023

Isofol initiates preclinical evaluation of arfolitixorin with Oncosyne AS

Invitation to presentation of Isofol´s report for the first quarter of 2023

Isofol Medical AB (publ) publishes annual report and corporate governance report for 2022

Isofols appoints Roy Jonebrant as new acting Chief Financial Officer

Isofol initiates a stepwise process for the continued development of its drug candidate arfolitixorin

Isofol’s board appoints Thomas Andersson as new CEO of the company

Bulletin from Extraordinary General Meeting in Isofol Medical AB (publ) held on February 28, 2023

Isofol Medical AB (publ) publishes year-end report, January – December 2022

Bulletin from Extraordinary General Meeting in Isofol Medical AB (publ) held on February 13, 2023

Invitation to presentation of Isofol´s report for the fourth quarter of 2022

Isofol has obtained a request to call for an extraordinary general meeting

Isofol invites to an informational meeting on January 30 prior to extraordinary general meeting

Notice convening the extraordinary general meeting in Isofol Medical AB (publ) 13 February 2023

Isofol Medical’s Board of Directors intends to call an extraordinary general meeting with proposals for dividends and liquidation of the company

Isofol Medical CFO and Deputy CEO Gustaf Albèrt to step down during 2023

CEO Ulf Jungnelius to leave Isofol Medical on June 1, 2023

Final data from the AGENT study confirms topline results

Isofol Medical AB (publ) publishes interim report, January–September 2022

Isofol appoints nomination committee ahead of the Annual General Meeting 2023

Invitation to presentation of Isofol’s report for the third quarter of 2022

Isofol reports data from the AGENT study

Isofol provides update on the AGENT study

Isofol Medical AB (publ) publishes interim report, January–June 2022

Invitation to presentation of Isofol´s report for the second quarter of 2022

Isofol Announces Topline Results of Phase III AGENT Study – Did Not Meet Primary or Key Secondary Endpoints

Isofol receives approval of biomarker analysis patent and intention-to-grant patent application for study dose regimen in Europe

Isofol updates start time of live-streamed R&D event on June 20 to 14:00 CEST

Isofol invites to a live-streamed R&D Event on June 20 at 12.30 CEST

Bulletin from Annual General Meeting in Isofol Medical AB (publ) held on May 19, 2022

Isofol Medical AB (publ) publishes interim report, January–March 2022

Invitation to presentation of Isofol’s report for the first quarter of 2022

Isofol Medical AB (publ) publishes annual report and corporate governance report for 2021

Isofol announces start of study data analysis of phase III AGENT study in advanced metastatic colorectal cancer

Notice to attend the Annual General Meeting held on May 19, 2022 in Isofol Medical AB (publ)

Isofol Medical AB’s (publ) Nomination Committee proposes New Chair of the Board

Isofol Medical AB (publ) publishes year-end report, January – December 2021